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Abstract 24	  
 25	  
The HepaRG cell line is a well-differentiated human hepatoma cell line proposed as a 26	  
surrogate for human hepatocytes, especially for hepatic detoxification studies. Polarized status 27	  
of drug transporters, i.e., their coordinated location at sinusoidal or canalicular membranes, 28	  
which represents a key hallmark of hepato-biliary drug transport, remains however 29	  
incompletely documented in HepaRG cells. The present study was therefore designed to 30	  
analyze transporter location in HepaRG cells, which exhibit mRNA expressions of most of 31	  
hepatic transporters. HepaRG cells were demonstrated, through immunofluorescence staining, 32	  
to express several drug transporters at their sinusoidal pole, especially the influx transporters 33	  
organic anion transporting polypeptide (OATP) 1B1, OATP2B1 and organic cation 34	  
transporter (OCT) 1 and the efflux transporter multidrug resistance-associated protein (MRP) 35	  
3. In addition, the efflux transporters P-glycoprotein and MRP2 were detected at the 36	  
canalicular pole of HepaRG cells.  Moreover, saturable uptake of reference substrates for the 37	  
sinusoidal transporters sodium-taurocholate cotransporting polypeptide, OATPs and OCT1 38	  
and canalicular secretion of reference substrates for the efflux transporters bile salt export 39	  
pump and MRP2 were observed.  This polarized and functional expression of various 40	  
sinusoidal and canalicular transporters in HepaRG cells highlights the interest of using these 41	  
hepatoma cells in xenobiotic transport studies. 42	  
 43	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1. Introduction 49	  
 The HepaRG cell line is a recently-characterized hepatic cell line, established from a 50	  
hepatocholangiocarcinoma of a female patient (Gripon et al., 2002). In contrast to most, if not 51	  
all, other available hepatic cell lines, the HepaRG cell line exhibits various liver-specific 52	  
functions and is therefore proposed as a surrogate for the use of primary human hepatocytes, 53	  
especially for xenobiotic metabolism and toxicity studies (Andersson et al., 2012; Guillouzo 54	  
et al., 2007). Indeed, when cultured in appropriate conditions, i.e., in the presence of 2 % 55	  
(vol/vol) dimethylsulfoxide (DMSO), HepaRG cells express high levels of hepatic drug 56	  
detoxifying pathways, including phase 1 enzymes, such as cytochromes P-450 1A2, 2B6 and 57	  
3A4, and phase 2 enzymes such as glutathione S-transferases A1/A2, A4 and M1 and UDP-58	  
glucuronosyl transferase 1A1 (Aninat et al., 2006; Antherieu et al., 2010). Moreover, HepaRG 59	  
cells exhibit notable expression of drug-sensing receptors such as the pregnane X receptor and 60	  
the constitutive androstane receptor (Antherieu et al., 2012) and are consequently responsive 61	  
to inducers of drug metabolism (Kanebratt and Andersson, 2008; Turpeinen et al., 2009).  62	  
 In addition to drug metabolizing enzymes, hepatic drug transporters are present and 63	  
functional in HepaRG cells	  (Kotani et al., 2012; Le Vee et al., 2006; Szabo et al., 2013). This 64	  
point is likely noteworthy, because the important roles played by hepatic drug transporters in 65	  
hepatic clearance of drugs and drug-induced cholestasis are now well-recognized (Giacomini 66	  
et al., 2010; Pauli-Magnus and Meier, 2006). Expression of transporters in HepaRG cells 67	  
remains however incompletely characterized, especially with respect to the polarization status 68	  
of these transporters.  Polarization into two complementary poles, i.e., a blood 69	  
sinusoidal/basolateral pole and a biliary apical/canalicular pole, represents a key hallmark of 70	  
differentiated hepatocytes and has important functional consequences in terms of hepato-71	  
biliary secretion of drugs (Chandra and Brouwer, 2004). Indeed, influx hepatic transporters 72	  
expressed at the sinusoidal/basolateral pole of hepatocytes mediate uptake of drugs from 73	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blood into liver, whereas canalicular transporters are responsible for secretion of drugs or 74	  
drug metabolites into bile (Funk, 2008; Kock and Brouwer, 2012). In addition, some efflux 75	  
transporters expressed at the sinusoidal membrane can secrete some drugs or drug metabolites 76	  
back into blood, for a secondary renal elimination (Zelcer et al., 2005) (See Fig. 1 for a 77	  
schematic overview of drug transporters expressed by human hepatocytes). The present study 78	  
was therefore designed to carefully analyze cellular location of several major sinusoidal and 79	  
canalicular hepatic transporters in HepaRG cells cultured under DMSO-based standard 80	  
conditions.  81	  
 82	  
2. Materials and methods 83	  
2.1 Chemicals  84	  
 Taurocholate, estrone-3-sulfate (E3S) and tetra-ethylammonium (TEA) were 85	  
purchased from Sigma-Aldrich (Saint-Quentin Fallavier, France), whereas carboxy-2,7-86	  
dichlorofluoresceine (CF) diacetate was provided by Invitrogen/Life Technologies (Villebon 87	  
sur Yvette, France). [3H(G)] taurocholic acid (sp. act. 1.19 Ci/mmol), [6, 7-3H(N)] E3S (sp. 88	  
act. 57.3 Ci/mmol) and [1-14C] TEA (sp. act. 2.4 mCi/mmol) were from Perkin-Elmer 89	  
(Boston, MA). All other chemicals were commercial products of the highest purity available. 90	  
 91	  
2.2 Cell culture  92	  
 Human highly-differentiated hepatoma HepaRG cells were routinely cultured in 93	  
Williams' E medium supplemented with 10% (vol/vol) fetal calf serum, 100 IU/ml penicillin, 94	  
100 µg/ml streptomycin, 5 µg/ml insulin, 2 mM glutamine, and 5 x 10–5 M hydrocortisone 95	  
hemisuccinate; additional culture for two weeks in the same medium supplemented with 2 % 96	  
(vol/vol) DMSO was performed in order to get a full hepatocytic differentiation of the cells 97	  
(Gripon et al., 2002).  98	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2.3 Preparation of freshly isolated human hepatocytes.  99	  
 Human hepatocytes were obtained from adult donors undergoing hepatic resection for 100	  
primary and secondary tumors, via the Biological Resource Center (Rennes, France), in 101	  
agreement with French laws and regulations and the local ethics committee. Cells were 102	  
prepared by perfusion of histologically-normal liver fragments using a collagenase solution as 103	  
previously described (Jigorel et al., 2005). They were immediately used for RNA isolation. 104	  
 105	  
2.4 RNA isolation and analysis  106	  
 Total RNA was isolated from cells using the TRIzol reagent (Invitrogen/Life 107	  
Technologies). RNA was then subjected to reverse transcription-quantitative polymerase 108	  
chain reaction (RT-qPCR), using the fluorescent dye SYBR Green methodology and an ABI 109	  
Prism 7300 detector (Applied Biosystem, Foster City, CA, USA), as previously reported 110	  
(Maubon et al., 2007). Gene primers were exactly as previously described (Le Vee et al., 111	  
2006; Moreau et al., 2011), except multidrug and toxin extrusion protein 1 112	  
(MATE1/SLC47A1) sense, GCAATCGCGGTTATCAATG, MATE1 antisense, 113	  
AAGCCTGGACACATCTGGG. Amplification curves were next analysed with ABI Prism 114	  
7000 SDS software using the comparative cycle threshold method. Relative quantification of 115	  
the steady-state target mRNA levels was calculated after normalization of the total amount of 116	  
cDNA tested to a 18S mRNA endogenous reference using the 2(−ΔCt)method. This allowed to 117	  
get a relative value of expression for each gene comparatively to the 18S RNA amount (20 118	  
ng) found in each RT-qPCR sample, arbitrarily set at 106 units (Moreau et al., 2011).   119	  
 120	  
2.5 Light and fluorescence microscopy 121	  
 Light microscopy and CF fluorescence were employed to monitor the presence of 122	  
functional canalicular networks in HepaRG cells, as previously described	  (Noel et al., 2013). 123	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For light microscopy studies, cells were observed using an Axiovert microscope (Carl Zeiss, 124	  
Le Pecq, France). For fluorescence studies, HepaRG cells were incubated with 3 µM CF 125	  
diacetate for 10 min at 37°C; cells were then washed with ice-cold phosphate-buffered saline 126	  
and visualized using a Leica DM IRB microscope (Leica Microsystems, Wetzlar, Germany) 127	  
equipped with a black/white CoolSNAP ES camera (Roper Scientific, Planegg/Martinsried, 128	  
Germany). Pictures were processed using the Metaview software. 129	  
 130	  
2.6 Immunolocalization studies 131	  
 Immunofluorescence analyses were performed as previously described (Vee et al., 132	  
2009). HepaRG cells cultured on glass coverslips were first fixed in ice-cold acetone for 10 133	  
min. Cells were next incubated for 3 h with mouse monoclonal antibodies diluted to 1:50 in 134	  
phosphate-buffered saline supplemented with 4 % (weight/weight) bovine serum albumin and 135	  
directed against organic cation transporter 1 (OCT1)/SLC22A1 (Abcam, Cambridge, UK), 136	  
multidrug resistance gene 1 (MDR1)/ABCB1/P-glycoprotein (Alexis Corporation, Lausen, 137	  
Switzerland), multidrug drug resistance-associated protein (MRP) 2/ABCC2 or 138	  
MRP3/ABCC3 (Millipore Bioscience Research Reagents, Temecula, CA), with rabbit 139	  
polyclonal antibodies diluted to 1:25 in the buffer described above and directed against 140	  
organic anion transporting polypeptide (OATP) 1B1/SLCO1B1 or OATP2B1/SLCO2B1 141	  
(Huber et al., 2007), or with corresponding mouse or rabbit isotypic Ig controls. After 142	  
washing, goat AlexaFluor 488- or AlexaFluor 546-labeled secondary antibodies 143	  
(Invitrogen/Life Technologies) were added for 1 h, and nuclei were subsequently stained with 144	  
4,6-diamidino-2-phenylindole. Immunofluorescence images were finally detected with a Zeiss 145	  
Axioskop A1 microscope (Carl Zeiss) and a Nikon DS-2MBW camera (Nikon, Champigny-146	  
sur-Marne, France), using the NIS-Elements F3.2 software (Nikon).  147	  
 148	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2.7 Drug transport assays  149	  
 For characterizing sinusoidal influx of taurocholate (a reference substrate for sodium 150	  
taurocholate co-transporting polypeptide (NTCP/SLC10A1)), of E3S (a reference substrate 151	  
for OATPs) and of TEA (a reference substrate for OCT1), HepaRG cells were incubated  at 152	  
37°C with 43.4 nM [3H] taurocholate, 3.4 nM [3H] E3S or  40 µM [14C] TEA in the absence 153	  
or presence of various concentrations of corresponding unlabelled substrates, using a defined 154	  
sodium- and calcium-containing transport assay medium (Jigorel et al., 2005). Incubation 155	  
times were 3 min (for taurocholate and E3S) or 5 min (for TEA); preliminary experiments 156	  
indicated that uptakes of these substrates were linear over these periods (data not shown). 157	  
After washing in phosphate-buffered saline, cells were lyzed and accumulation of 158	  
radiolabelled substrates was determined through scintillation counting. Kinetic parameters 159	  
(Km and Vmax) of taurocholate, E3S and TEA uptake in HepaRG cells were next estimated 160	  
though fitting data with Prism software (GraphPad software, La Jolla, CA) to Michaelis-161	  
Menten plots based on the following equation:  162	  
    v = (Vmax x [S])/(Km + |S])  163	  
where v is the initial uptake rate of substrate, [S] is the substrate concentration in the 164	  
medium, Km is the Michaelis–Menten constant, and Vmax is the maximum uptake rate.  165	  
 Biliary secretion of taurocholate and CF was analyzed through determination of drug 166	  
accumulation into bile canaliculi-like structures as previously reported (Annaert et al., 2001). 167	  
Briefly, HepaRG cells were first incubated for 10 min at 37°C with transport assay buffer 168	  
containing Ca2+ or with the same buffer, except that 1.8 mM CaCl2 was withdrawed and 100 169	  
µM EGTA was added, knowing that incubation with this Ca2+-free buffer promotes disruption 170	  
of tight junctions and opening of bile canaliculi networks. Buffers were then removed and 171	  
HepaRG cells were further incubated for 10 min at 37°C in transport assay medium 172	  
containing 43.4 nM [3H] taurocholate or 3 µM CF diacetate. After washing with ice-cold 173	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phosphate-buffered saline, accumulations of taurocholate and CF into cells + bile canaliculi 174	  
(Ca2+-containing conditions) and into cells only (Ca2+-free conditions) were determined by 175	  
scintillation counting (for taurocholate) or spectrofluorimetry (for CF) using a SpectraMax 176	  
Gemini SX spectrofluorometer (Molecular Devices, Sunnyvale, CA) (excitation and emission 177	  
wavelengths were 485 and 535 nm, respectively). Biliary excretion index (BEI) was finally 178	  
calculated using the following equation (Liu et al., 1999): 179	  
 180	  
2.8 Statistical analysis. Quantitative data were statistically analyzed using Student’s t-test or 181	  
nonparametric Spearman’s rank correlation method. The criterion of significance 182	  
was p < 0.05.   183	  
 184	  
3. Results 185	  
 mRNA expression of sinusoidal and canalicular drug transporters in HepaRG cells 186	  
was first characterized by RT-qPCR and compared to that found in freshly isolated human 187	  
hepatocytes; these freshly isolated human hepatocytes were obtained from 8 donors, in order 188	  
to take into consideration potential inter-individual differences in drug transporter mRNA 189	  
levels. As shown in Fig. 2, expressions of sinusoidal influx solute carrier (SLC) transporters 190	  
such as NTCP, OATPs, OCT1 and organic anion transporter 2 (OAT2/SLC22A7), were 191	  
reduced in HepaRG cells when compared to hepatocytes. Nevertheless, when considering 192	  
mRNA levels expressed in arbitrary units, substantial expressions (> 5 arbitrary units) of 193	  
NTCP, OATP1B1, OATP2B1, OCT1 and OAT2 were detected in HepaRG cells, knowing 194	  
that these transporters were otherwise highly expressed in freshly isolated human hepatocytes 195	  
(Fig. 2). Only OATP1B3, which was markedly down-regulated in HepaRG cells when 196	  
Accumulation (Cells+Bile canaliculi)
BEI= 
Accumulation (Cells+Bile canaliculi) – Accumulation (Cells)
X 100
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compared to hepatocytes, was finally very poorly expressed in HepaRG cells (expression < 1 197	  
arbitrary unit). In contrast to SLC transporters, sinusoidal ATP-binding cassette (ABC) efflux 198	  
transporters, except MRP6 (ABCC6), were up-regulated in HepaRG cells when compared to 199	  
human hepatocytes (Fig. 2); mRNA levels of MRP1, MRP4 and MRP5, which are very 200	  
poorly expressed in human hepatocytes (expression <1 arbitrary unit), remained however also 201	  
low in HepaRG cells (expression < 5 arbitrary units), unlike that of MRP3 (expression = 45.0 202	  
arbitrary units). With respect to canalicular transporters, some of them, such as MRP2 and 203	  
especially MDR1, were induced in HepaRG cells, when compared to human hepatocytes (Fig. 204	  
3). By contrast, the canalicular SLC transporter MATE1 remained unchanged, whereas breast 205	  
cancer resistance protein (BCRP/ABCG2) and especially bile salt export pump 206	  
(BSEP/ABCB11) were down-regulated (Fig. 3).  207	  
 To more globally characterize drug transporter expression in HepaRG cells and human 208	  
hepatocytes, sinusoidal and canalicular drug transporters were next ranked from the most 209	  
expressed to the less expressed according to mRNA level of expression and the resulting 210	  
expression profiles were compared. As shown in Fig. 4, expression profile of drug 211	  
transporters in HepaRG cells was close to that exhibited by freshly isolated human 212	  
hepatocytes, even if the correlation failed to reach a significant level (p=0.07).  213	  
 DMSO-treated differentiated HepaRG cells are well-known to be polarized (Antherieu 214	  
et al., 2012) and consequently exhibit bile canaliculi-like structures, which accumulated the 215	  
fluorescent dye CF (Fig. 5A), indicating that they were fully functional. Immunofluorescence 216	  
staining next revealed that various hepatic transporters such as OATP1B1, OATP2B1, OCT1 217	  
and MRP3, known to be physiologically present at the sinusoidal pole of hepatocytes in the 218	  
liver (Funk, 2008) (Fig. 1), were similarly expressed at the sinusoidal pole of cultured 219	  
HepaRG cells (Fig. 5B).  In the same way, the canalicular ABC transporters MDR1/P-220	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glycoprotein and MRP2 were located to the bile canaliculi-like structures of HepaRG cell 221	  
cultures (Fig. 5B). 222	  
 HepaRG cells have previously been shown to exhibit sinusoidal transport activity, 223	  
especially NTCP-mediated uptake of taurocholate, OATP-mediated uptake of E3S, estradiol-224	  
17β glucuronide and pitavastatin, and OCT1-mediated uptake of TEA (Kotani et al., 2012; Le 225	  
Vee et al., 2006; Szabo et al., 2013). In order to better characterize some of these sinusoidal 226	  
transport activities, we determined their kinetic parameters. As shown in Fig. 6A, uptakes of 227	  
taurocholate, E3S and TEA in HepaRG cells were found to be saturable, with Km values in 228	  
the µM range (for taurocholate and E3S) and in the mM range (for TEA).  229	  
 Canalicular secretion of taurocholate and CF was finally quantified in HepaRG cells 230	  
using the BEI approach based on Ca2+ withdrawal-mediated disruption of canaliculi (Liu et 231	  
al., 1999). As shown in Fig. 6B, HepaRG cells pre-incubated in Ca2+-free conditions exhibited 232	  
decreased retention of taurocholate and CF comparatively to counterparts maintained in the 233	  
presence of Ca2+. This indicated that HepaRG cells secreted taurocholate and CF in bile 234	  
canaliculi-like structures, in agreement, for CF, with Fig. 5A, and permitted to calculate BEI 235	  
values (34.4 % and 29.2 % for CF and taurocholate, respectively).   236	  
 237	  
 238	  
 239	  
 240	  
 241	  
 242	  
 243	  
 244	  
 245	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4. Discussion 246	  
 The data reported in the present study indicate that HepaRG cells exhibit polarized 247	  
expression of sinusoidal and canalicular drug transporters and thus complete previous studies 248	  
characterizing expression of drug transporters in these well-differentiated human hepatoma 249	  
cells (Kotani et al., 2012; Le Vee et al., 2006; Szabo et al., 2013). 250	  
 Most of sinusoidal and canalicular transporters were expressed at notable mRNA 251	  
levels in HepaRG cells, with  a global profile of transporter expression close to that displayed 252	  
by freshly isolated human hepatocytes. These data fully confirm previous findings	  (Antherieu 253	  
et al., 2012), knowing however that freshly isolated human hepatocytes were chosen as 254	  
reference cells in the present study, in contrast to previous ones using primary hepatocytes or 255	  
cryopreserved hepatocytes as references for investigating transporter expression in HepaRG 256	  
cells (Antherieu et al., 2010; Kotani et al., 2012; Le Vee et al., 2006); this point has likely to 257	  
be underlined, because placing hepatocytes in culture or hepatocyte cryopreservation are 258	  
susceptible to alter drug detoxifying protein expression and activity, including those of 259	  
transporters (Badolo et al., 2011; Ramboer et al., 2013). It is also noteworthy that some 260	  
transporters that have not previously investigated in HepaRG cells, such as the canalicular 261	  
SLC transporter MATE1 and the sinusoidal ABC transporter MRP6, were reported to be 262	  
expressed by these hepatoma cells in the present study.  Among transporters, some 263	  
discrepancies between mRNA levels in HepaRG cells and freshly isolated human 264	  
hepatocytes, were nevertheless observed; it is notably the case for OATP1B3, which was very 265	  
poorly expressed in HepaRG cells, in agreement with a recent report (Kotani et al., 2012), 266	  
making not appropriate the use of HepaRG cells for studying transport of specific substrates 267	  
of this OATP isoform. In the same way, some ABC efflux transporters, especially MDR1, 268	  
MRP1, MRP4 and MRP5, were highly expressed in HepaRG cells when compared to freshly 269	  
isolated human hepatocytes. Some of these transporters such as MRP1, MRP4 and MRP5 270	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remain however among the less expressed transporters in HepaRG cells (Fig. 4), with low 271	  
absolute mRNA levels (< 5 arbitrary units). This may be consistent with a low background 272	  
expression for MRP1, MRP4 and MRP5, even in HepaRG cells. Interestingly, up-regulation 273	  
of the ABC efflux pumps MDR1, MRP1, MRP4 and MRP5 also occurs in primary rodent 274	  
hepatocytes when compared to parental freshly isolated hepatocytes (Fardel et al., 1992; Noel 275	  
et al., 2013) and it may therefore be interpreted as an adaptative/protective cellular response 276	  
towards an in vitro unfamiliar environment.   277	  
 Because expression of some transporters such as MRP2 is sometimes largely restricted 278	  
to intracellular pools in hepatocytes (Roma et al., 2008) and therefore may not correlate with 279	  
transport function, accurate characterization of transporter location in HepaRG cells is likely a 280	  
key parameter to consider. In this context, notable mRNA expression of the major sinusoidal 281	  
hepatic transporters OATP1B1, OATP2B1, OCT1 and MRP3 was associated with the 282	  
detection of the corresponding proteins at the sinusoidal pole of HepaRG cells through 283	  
immunofluorescence staining; in the same way, the biliary ABC transporters P-glycoprotein 284	  
and MRP2 were found to be present at the canalicular pole of hepatocytes. Taken together, 285	  
these data indicate a correct location of both sinusoidal and canalicular drug transporters in 286	  
HepaRG cells. This point is likely important to consider for using HepaRG cells in drug 287	  
transport studies, because polarized localization of transporters is crucial for in vitro models 288	  
of hepatic drug transport, and is well-exhibited by the present gold standard of these models, 289	  
i.e., sandwich-cultured hepatocytes (Swift et al., 2010).  290	  
 Transporters correctly located at the sinusoidal pole HepaRG cells were moreover 291	  
fully functional. In particular, uptake of taurocholate in HepaRG cells was found to be 292	  
saturable, with a Km value (6.3 µM) closed to that described for NTCP-mediated taurocholate 293	  
in NTCP-transfected cells (Km=7.9 µM) (Kim et al., 1999). E3S uptake was also saturable in 294	  
HepaRG cells (Fig. 6A), with a Km value (44.0 µM) nearly identical to that corresponding to 295	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the low-affinity binding site for OATP1B1-mediated E3S transport in OATP1B1-transfected 296	  
cells (Km=45.0 µM)	   (Noe et al., 2007). A contribution of the high-affinity binding site of 297	  
OATP1B1 for E3S (Km=0.09 µM) (Tamai et al., 2001) and of OATP2B1, which is well 298	  
known to transport E3S (Km=10.2 µM) (Noe et al., 2007) and is expressed in HepaRG cells at 299	  
substantial level (Fig. 2), has however likely to be additionally taken into consideration for 300	  
E3S influx in HepaRG cells. By contrast, a role for OATP1B3 may be discarded, since this 301	  
transporter is only present at a very low level in HepaRG cells (Fig. 2). TEA uptake was also 302	  
found to be saturable in HepaRG cells (Fig. 6A), with however a Km value (1.44 mM) higher 303	  
than those reported for TEA uptake in OCT1-transfected cells, that ranged from 69.2 µM to 304	  
229.0 µM (Umehara et al., 2007; Zhang et al., 1998). The reason for such a discrepancy 305	  
between Km values for TEA uptake in OCT1-expressing HepaRG cells versus OCT1-306	  
transfected cells remains to be clarified; it could be linked to post-transcriptional processes 307	  
specifically targeting OCT1 in HepaRG cells, such as phosphorylation or glycosylation, or, 308	  
alternatively, to the artificially elevated levels of OCT1 in OCT1-transfected cells. 309	  
 Like sinusoidal transporters, canalicular transporters were functional in HepaRG cells. 310	  
Indeed, both CF and taurocholate secretion into bile canaliculi-like structures of HepaRG cells 311	  
were demonstrated and quantitatively characterized in the present study, allowing to 312	  
determine BEI values (Fig. 6B). Interestingly, BEI value for CF in HepaRG cells (34.4 %) 313	  
was nearly identical to CF BEI value reported in sandwich-cultured human hepatocytes 314	  
(BEI=34%)	  (Hoffmaster et al., 2004), which suggests that MRP2 is similarly active in these 315	  
primary human hepatocytes and in HepaRG cells. By contrast, taurocholate BEI values in 316	  
sandwich-cultured human hepatocytes (around 70-75%) (Marion et al., 2007) are rather 317	  
higher than that found in HepaRG cells (BEI=29.2%), which likely indicates a lower BSEP 318	  
activity in HepaRG cells, consistent with the rather reduced BSEP mRNA expression in these 319	  
hepatoma cells when compared to freshly isolated human hepatocytes (Fig. 3). Interestingly, 320	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BEI value, a useful in vitro parameter for predicting hepatobiliary drug disposition (Liu et al., 321	  
1999), is usually determined only from sandwich-cultured hepatocytes (De Bruyn et al., 322	  
2013), because monolayer-cultured hepatocytes failed to get polarization status and to exhibit 323	  
functional bile canaliculi; the fact that BEI values can also be determined from HepaRG cells, 324	  
that are not cultured on a sandwich configuration, is therefore noteworthy. Further studies are 325	  
however required to fully confirm the feasibility of using HepaRG cells for in vitro 326	  
determination of BEI for various structurally-unrelated drugs and to next determine whether 327	  
such BEI determined from these cultured hepatoma cells may be really relevant for the 328	  
prediction of hepatobiliary disposition of xenobiotics. In addition, it may be rather interesting 329	  
to determine whether culturing HepaRG cells in a matrigel- or collagen-based sandwich 330	  
configuration may improve activity of some canalicular efflux transporters, especially that of 331	  
BSEP. 332	  
 In summary, HepaRG cells were demonstrated to exhibit a polarized and functional 333	  
expression of various major sinusoidal and canalicular drug transporters. Otherwise, HepaRG 334	  
cells have been shown to be fully responsive to physiological, pharmacological or 335	  
toxicological stimuli regulating hepatic transporter expression (Fardel and Le Vee, 2009; 336	  
Lambert et al., 2009) and to be targeted by drugs inducing cholestasis through alteration of 337	  
bile acid transporter activity (Antherieu et al., 2013; Szabo et al., 2013). Taken together, these 338	  
data clearly highlight the interest of using HepaRG cells in drug transport studies as 339	  
surrogates for human hepatocytes, even if some quantitative differences between HepaRG 340	  
cells and human hepatocytes with respect to transporter expression levels and transport 341	  
parameters exist and have likely to be kept in mind.  342	  
 343	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Legends to figures 493	  
 494	  
Fig. 1. Schematic overview of drug transporters expressed at the sinusoidal and canalicular 495	  
poles of human hepatocytes. 496	  
 497	  
Fig. 2. Sinusoidal drug transporter mRNA expression in HepaRG cells. 498	  
Expression of sinusoidal drug transporter expression was determined in HepaRG cells and 499	  
freshly isolated human hepatocytes (FIHH) by RT-qPCR as described in Materials and 500	  
Methods. Data from 8 independent HepaRG cell cultures and from 8 independent hepatocyte 501	  
populations are expressed as boxplots, knowing that each HepaRG cell culture and each 502	  
hepatocyte population were analyzed in duplicate. Transporter expressions in HepaRG cells 503	  
expressed as % of that found in human hepatocytes (arbitrarily set at 100 %) are indicated by 504	  
numbers in brackets.*, p<0.05 when compared to hepatocytes.  505	  
 506	  
Fig. 3. Canalicular drug transporter mRNA expression in HepaRG cells. 507	  
Expression of canalicular drug transporter expression was determined in HepaRG cells and 508	  
freshly isolated human hepatocytes (FIHH) by RT-qPCR as described in Materials and 509	  
Methods. Data from 8 independent HepaRG cultures and from 8 independent hepatocyte 510	  
populations are expressed as boxplots, knowing that each HepaRG cell culture and each 511	  
hepatocyte population were analyzed in duplicate. Transporter expressions in HepaRG cells 512	  
expressed as % of that found in human hepatocytes (arbitrarily set at 100 %) are indicated by 513	  
numbers in brackets.*, p<0.05 when compared to hepatocytes.  514	  
 515	  
 516	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Fig. 4. Comparison of drug transporter expression profiles in HepaRG cells and freshly 517	  
isolated human hepatocytes. 518	  
 Drug transporters were ranked according to their level of mRNA expression; correlation 519	  
between transporter expression profiles was next analyzed using the Spearman's rank 520	  
correlation method. Spearman's rank coefficient (ρ) and p values are indicated at the top of 521	  
the correlation graph. 522	  
 523	  
Fig. 5. Drug transporter localization in HepaRG cells. 524	  
(A) HepaRG cell morphology was examined by light phase contrast microscopy whereas CF-525	  
labeled functional bile canaliculi were detected through fluorescence microscopy; bile 526	  
canaliculi are indicated by arrows. Bar = 30 µM. (B) Immunolocalization of sinusoidal and 527	  
canalicular drug transporters was performed as described in Materials and Methods. Pictures 528	  
correspond to single immunolabeling, with membrane transporter-related green fluorescence, 529	  
except bottom right picture, for which double immunolabeling was performed (red 530	  
fluorescence for MRP2 and green fluorescence for OATP1B1); blue fluorescence corresponds 531	  
to 4,6-diamidino-2-phenylindole-stained nuclei. Data shown are representative of three 532	  
independent experiments. Bar = 10 µM. 533	  
 534	  
Fig. 6. Sinusoidal (A) and canalicular (B) drug transport activity in HepaRG cells. 535	  
(A) Saturable uptakes of reference substrates for sinusoidal transporters (Taurocholate for 536	  
NTCP, E3S for OATPs and TEA for OCT1) were analyzed as described in Materials and 537	  
Methods. Data are the means + SEM of three independent experiments, each being performed 538	  
in duplicate. Kinetic parameters (Km, Vmax) are indicated on the top of each graph. (B) 539	  
Canalicular secretions of the BSEP substrate taurocholate and the MRP2 substrate CF were 540	  
determined as described in Material and Methods. Data are the means + SEM of five 541	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(Taurocholate) or four (CF) independent experiments, each being performed in triplicate. BEI 542	  
values are indicated on the top of each graph. *, p<0.05 (paired Student’s t-test). FAU, 543	  
fluorescence arbitrary unit. 544	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